NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2023

5. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of June 30,		As of December 31,
	2023		2022
	Unaudited		Unaudited
Accrued compensation and benefits	$	579,171	$	171,572
Accrued consulting settlement		75,000		225,000
Accrued professional fees		162,435		241,808
Accrued research and development		10,009		20,684
Accrued franchise tax		29,680		217,440
Accrued restructuring		—		316,032
Other accrued expenses		195,206		35,120
Total	$	1,051,501	$	1,227,656